Transthyretin Amyloidosis Treatment Market: Market Size & Forecast 2026

ATTR occurs when transthyretin, a liver-produced transport protein carrying thyroid hormone and vitamin A, misfolds and forms amyloid deposits. The condition manifests primarily as transthyretin amyloid cardiomyopathy (ATTR-CM), affecting the heart, and polyneuropathy forms that damage peripheral nerves. Once considered untreatable, the therapeutic landscape has transformed with disease-modifying agents that stabilize the TTR protein or reduce its production.

• •ATTR is caused by mutations in the TTR gene or wild-type protein misfolding associated with aging
• •The disease predominantly affects cardiac tissue, peripheral nerves, and sometimes the carpal tunnel and lumbar spine
• •Historically underdiagnosed due to symptom overlap with more common conditions like heart failure and neuropathy

Advancements in diagnostic capabilities have dramatically increased ATTR detection rates, with non-invasive scintigraphy and genetic testing now enabling earlier identification. Regulatory approvals of multiple transthyretin stabilizers and RNA interference therapies have created a competitive treatment environment that fuels market expansion. Growing recognition among cardiologists and neurologists has expanded the treatable patient population beyond previously identified cases.

• •FDA and EMA approvals for tafamidis, acoramidis, and RNAi therapies have validated the commercial opportunity
• •Increased screening of heart failure patients has uncovered previously undiagnosed ATTR-CM cases
• •Long-term safety and efficacy data demonstrating disease modification have strengthened payer reimbursement

The market segments by disease type, with ATTR-CM representing the largest and fastest-growing segment due to higher disease prevalence and successful treatment outcomes. Geographic distribution shows North America leading market share, followed by Europe and emerging markets in Asia-Pacific where diagnostic infrastructure continues improving. Treatment approaches vary between TTR stabilizers that prevent protein misfolding and gene-silencing therapies that reduce TTR production at the source.

• •ATTR-CM dominates market share, while ATTR with polyneuropathy represents a significant segment, particularly in endemic regions
• •North America accounts for the largest regional share driven by advanced diagnostic capabilities and treatment access
• •Japan and select European countries show high uptake due to earlier adoption of screening protocols for cardiac amyloidosis

What are the recent trends and outlook?

The market's 13.5% growth rate reflects expanding indications, combination therapy research, and the pipeline of next-generation treatments with improved safety profiles. Subcutaneous and oral formulations in development promise to enhance patient convenience and adherence compared to existing infusion regimens. The ongoing shift toward population-wide screening for ATTR in cardiac and geriatric populations suggests continued patient pool expansion through 2030 and beyond.

• •Research into combination therapies pairing stabilizers with gene-silencing agents aims to address both wild-type and hereditary disease forms
• •Oral TTR stabilizers under investigation could significantly broaden treatment accessibility
• •Integration of ATTR screening into standard cardiac workup protocols is expected to accelerate early intervention and market penetration